MedTrace Logo

Study of Single and Multiple Doses of PRS-220 Administered by Oral Inhalation in Healthy Subjects

NCT05473533 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-10-23

No results posted yet for this study

Summary

A dose escalating study of PRS-220 administered by oral inhalation in healthy subjects

Conditions

  • Healthy

Interventions

DRUG

Placebo

Placebo; formulated as solution for inhalation without active substance.

DRUG

PRS-220

PRS-220; formulated as solution for inhalation.

Sponsors & Collaborators

  • Pieris Australia Pty Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-31
Primary Completion
2023-08-11
Completion
2023-08-11

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05473533 on ClinicalTrials.gov